Document Detail


Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma.
MedLine Citation:
PMID:  12060117     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Rituximab has significant activity as a single agent in the treatment of follicular non-Hodgkin's lymphoma (NHL). Interleukin 2 (IL-2) is a lymphokine that increases effector cell number. In an effort to augment antibody-dependent cell-mediated cytotoxicity (ADCC) associated with rituximab therapy, low-dose IL-2 was added to a standard rituximab regimen and patients were evaluated for safety and efficacy. Twenty patients with relapsed or refractory follicular NHL were treated with IL-2 (1.2 MIU/m(2)/d for 56 d subcutaneously) as outpatients. Rituximab (375 mg/m(2)) was given on d 15, 22, 29 and 36. The regimen was well tolerated and only three patients required dose adjustments in IL-2. Infusional toxicity associated with rituximab was not exacerbated by IL-2. Peripheral blood immunophenotyping demonstrated significant increases in circulating CD8+ and CD56+ lymphocytes in all evaluable patients (P = 0.0002). Increases in total eosinophil number were observed in all patients. Eleven patients responded to therapy, for an overall response rate of 55%. Four additional patients had stable disease. For these 15 patients, the median time to progression exceeded 13 months. We conclude concomitant cytokine therapy to enhance ADCC with monoclonal antibody therapy was well tolerated and did not exacerbate antibody-related infusional toxicity. Further studies of this rational combination are warranted and ongoing.
Authors:
Jonathan W Friedberg; Donna Neuberg; John G Gribben; David C Fisher; Christine Canning; Margaret Koval; Christine M Poor; Luke M Green; John Daley; Robert Soiffer; Jerome Ritz; Arnold S Freedman
Related Documents :
2428947 - A 10-year update of chop-bleo in the treatment of diffuse large-cell lymphoma.
16167027 - First-line treatment of follicular lymphoma in the era of monoclonal antibodies.
12746167 - Anti-cd20 monoclonal antibody (rituximab) for therapy of mediastinal cd20-positive larg...
16206217 - Acute renal failure in african children with burkitt's lymphoma: a comparison of two tr...
9338727 - Intravesical immunoprophylaxis in recurrent superficial bladder cancer (stage t1): mult...
23482807 - Exclusive electron intraoperative radiotherapy in early-stage breast cancer: a monoinst...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  British journal of haematology     Volume:  117     ISSN:  0007-1048     ISO Abbreviation:  Br. J. Haematol.     Publication Date:  2002 Jun 
Date Detail:
Created Date:  2002-06-12     Completed Date:  2002-09-10     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  0372544     Medline TA:  Br J Haematol     Country:  England    
Other Details:
Languages:  eng     Pagination:  828-34     Citation Subset:  IM    
Affiliation:
Department of Adult Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. jfriedberg@partners.org
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Antibodies, Monoclonal / adverse effects,  therapeutic use*
Antibody-Dependent Cell Cytotoxicity
Antigens, CD56 / immunology
CD8-Positive T-Lymphocytes / immunology
Chromosomes, Human, Pair 14
Chromosomes, Human, Pair 18
Drug Administration Schedule
Drug Therapy, Combination
Eosinophils / immunology
Female
Follow-Up Studies
Gene Rearrangement
Humans
Interleukin-2 / adverse effects,  therapeutic use*
Lymphoma, Follicular / drug therapy*,  genetics,  immunology
Male
Middle Aged
Recurrence
T-Lymphocytes / immunology
Grant Support
ID/Acronym/Agency:
CA 66996/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antigens, CD56; 0/Interleukin-2; 0/rituximab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Evidence that continued remission in patients treated for acute leukaemia is dependent upon autologo...
Next Document:  Marrow matrix metalloproteinases (MMPs) and tissue inhibitors of MMP in acute leukaemia: potential r...